Lower Circulating miR-122 Level in Patients with HNF1A Variant-Induced Diabetes Compared with Type 2 Diabetes

Abstract EN

miR-122, the expression of which is regulated by several transcription factors, such as HNF1A, was recently reported to be associated with type 2 diabetes (T2DM) and hepatocellular carcinoma.

HNF1A variants can cause diabetes and might be involved in the development of primary liver neoplasm.

Differences in miR-122 expression among different types of diabetes have not been studied.

This study aimed to investigate differences in serum miR-122 levels in Chinese patients with different forms of diabetes, including T2DM, type 1 diabetes (T1DM), HNF1A variant-induced diabetes (HNF1A-DM), glucokinase variant-induced diabetes (GCK-DM), and mitochondrial A3243G mutation-induced diabetes (MDM).

In total, 12 HNF1A-DM patients, 24 gender-, age-, and body mass index-matched (1 : 2) T2DM patients and 24 healthy subjects were included in this study.

In addition, 30 monogenic diabetes (11 GCK-DM and 19 MDM) and 17 T1DM patients were included.

Fasted blood biochemistry and miR-122 were measured.

The results showed that the HNF1A-DM patients had lower miR-122 levels [0.046 (0.023, 0.121)] than T2DM patients [0.165 (0.036, 0.939), P=0.02] and healthy controls [0.249 (0.049, 1.234), P=0.019].

The area under the curve of the receiver operating characteristic curve for miR-122 to discriminate HNF1A-DM and T2DM was 0.687 (95% CI: 0.52–0.86, P=0.07).

There was no difference in serum miR-122 among HNF1A-DM, GCK-DM, MDM, and T1DM patients.

Lower serum miR-122 is a unique feature of HNF1A-DM patients and might partially explain the increased risk for liver neoplasm and abnormal lipid metabolism in HNF1A-DM patients.